公开(公告)号：US20220323385A1

公开(公告)日：2022-10-13

申请号：US17620406

申请日：2020-06-19

Applicant: KINKI UNIVERSITY ,  YASHIRO CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Nobuhiro ZAIMA ,  Hirona KUGO ,  Motohiro KITANO ,  Yoshinori HIROTA ,  Ken-ichi HIRANO

IPC: A61K31/19 ,  A61P9/14 ,  A61K38/00

Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.

公开(公告)号：US20230251278A1

公开(公告)日：2023-08-10

申请号：US18014582

申请日：2021-07-07

Applicant: OSAKA UNIVERSITY ,  RIKEN ,  NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY

Inventor： Ken-ichi HIRANO ,  Yasuhiro HARA ,  Hirokazu KASHIWAGI ,  Akira SUZUKI ,  Takashi JIN ,  Kenji MONDE ,  Yuta MURAI

IPC: G01N33/92 ,  G01N33/533 ,  C07C229/34

CPC classification number: G01N33/92 ,  G01N33/533 ,  C07C229/34 ,  G01N2800/323 ,  G01N2800/7085 ,  G01N2800/325

Abstract: Provided are a method for acquiring a value relating to a triglyceride metabolic capacity of a subject within a shorter period of time compared to conventional nuclear medicine methods, and a test reagent and a test kit that are to be used in the acquisition method. This problem can be solved by an acquisition method of a value relating to the triglyceride metabolic capacity in leucocytes of a subject, said method comprising: a first step of mixing, in vitro, a fatty acid compound labeled with a fluorescent substance with leucocytes collected from the subject and thus bringing the fatty acid labeled with the fluorescent substance into contact with the leucocytes, wherein the fatty acid compound contains a fatty acid residue, the fatty acid residue has 8-26 carbon atoms, and a part of hydrogen atoms constituting the fatty acid residue, excluding a terminal methyl group of the fatty acid residue, may be substituted by an alkyl group having 1-3 carbon atoms; and a second step of acquiring, as the value relating to the triglyceride metabolic capacity, a measured fluorescence intensity that is derived from the fluorescent label in the leucocytes.

公开(公告)号：US20240065992A1

公开(公告)日：2024-02-29

申请号：US18266070

申请日：2021-12-10

Applicant: KINKI UNIVERSITY ,  YASHIRO CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Nobuhiro ZAIMA ,  Hirona KUGO ,  Motohiro KITANO ,  Yoshinori HIROTA ,  Ken-ichi HIRANO

IPC: A61K31/19 ,  A61P9/00

CPC classification number: A61K31/19 ,  A61P9/00

Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.

公开(公告)号：US20230210805A1

公开(公告)日：2023-07-06

申请号：US17926301

申请日：2021-03-05

Applicant: OSAKA UNIVERSITY

Inventor： Ken-ichi HIRANO

IPC: A61K31/225 ,  A61P9/10

CPC classification number: A61K31/225 ,  A61P9/10

Abstract: The present invention provides an agent for inducing regression of triglyceride (TG) deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, an agent for improving blood flow in a patient with TG deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, and a pharmaceutical or food or drink product comprising the agent for inducing regression of TG deposit atherosclerosis or the agent for improving blood flow.